Literature DB >> 29720865

Use of vedolizumab in a patient with chronic and refractory pouchitis.

Eleni Orfanoudaki1, Kalliopi Foteinogiannopoulou1, Ioannis E Koutroubakis1.   

Abstract

Entities:  

Year:  2018        PMID： 29720865      PMCID： PMC5924862          DOI： 10.20524/aog.2018.0243

Source DB:  PubMed          Journal:  Ann Gastroenterol        ISSN： 1108-7471


× No keyword cloud information.
  3 in total

1.  Efficacy of Vedolizumab in Patients with Antibiotic and Anti-tumor Necrosis Alpha Refractory Pouchitis.

Authors:  Jessica Philpott; Jean Ashburn; Bo Shen
Journal:  Inflamm Bowel Dis       Date:  2017-01       Impact factor: 5.325

2.  Successful Treatment With Vedolizumab in a Patient With Chronic Refractory Pouchitis and Primary Sclerosing Cholangitis.

Authors:  M Coletta; M Paroni; F Caprioli
Journal:  J Crohns Colitis       Date:  2017-12-04       Impact factor: 9.071

3.  Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis.

Authors:  F Bär; T Kühbacher; N A Dietrich; T Krause; A Stallmach; N Teich; S Schreiber; J Walldorf; R Schmelz; C Büning; K Fellermann; J Büning; U Helwig
Journal:  Aliment Pharmacol Ther       Date:  2017-12-19       Impact factor: 8.171
  3 in total
  1 in total

1.  α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis.

Authors:  Michaela Melde; Tanja M Müller; Ines Schneider; Carol-Immanuel Geppert; Laura Mühl; Laura Besendorf; Clarissa Allner; Emily Becker; Imke Atreya; Francesco Vitali; Raja Atreya; Markus F Neurath; Sebastian Zundler
Journal:  Therap Adv Gastroenterol       Date:  2021-11-24       Impact factor: 4.409
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.